Patents by Inventor Ian Linney

Ian Linney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPK1 antagonists and uses thereof
    Patent number: 11926625
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: March 12, 2024
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Benjamin Whittaker, William Sinko, Shawn Watts, Mark Anthony Ashwell, Byron Scott Delabarre
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20240025898
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: July 11, 2023
    Publication date: January 25, 2024
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • Urolithin derivatives and methods of use thereof
    Patent number: 11820751
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 21, 2023
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20230117631
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: March 4, 2022
    Publication date: April 20, 2023
    Inventors: Neelu KAILA, Ian Linney, Stuart Ward, Grant Wishart, Benjamin Whittaker, William Sinko, Shawn Watts, Mark Anthony Ashwell, Byron Scott Delabarre
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20230096641
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: February 11, 2022
    Publication date: March 30, 2023
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Benjamin WHITTAKER, William SINKO, Shawn WATTS, Mark Anthony ASHWELL, Byron Scott DELABARRE
  • HPK1 antagonists and uses thereof
    Patent number: 11548890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 10, 2023
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20220363695
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: March 29, 2022
    Publication date: November 17, 2022
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Benjamin WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11078201
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 3, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11034694
    Abstract: The present invention provides compounds of formula I: or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof. The present invention also provides methods for the inhibition of HPK1 and methods for the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 15, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists
    Patent number: 11028085
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11021481
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087189
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087190
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20210078996
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078998
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078997
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 10196386
    Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 5, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Aminoester derivatives
    Patent number: 10117860
    Abstract: Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: November 6, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Carmelida Capaldi, Wesley Blackaby, Ian Linney, Hervé Van De Poël, Charles Baker-Glenn, Naimisha Trivedi
  • Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
    Patent number: 10004728
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 26, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
    Patent number: 9932338
    Abstract: Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 3, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Laura Carzaniga, Fabio Rancati, Andrea Rizzi, Ian Linney